Valuation: Oncotelic Therapeutics, Inc.

Market Cap 7.73M 6.9M 6.38M 5.78M 10.81M 734M 10.99M 76.76M 30.39M 385M 29.02M 28.4M 1.21B P/E 2024
-3.13x
P/E 2025 0.13x
Enterprise Value 21.56M 19.25M 17.78M 16.11M 30.15M 2.05B 30.65M 214M 84.72M 1.07B 80.9M 79.18M 3.38B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
56.48%
Yield 2024 *
-
Yield 2025 -
08-13 Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-02 Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc CI
07-22 Oncotelic Therapeutics, Inc. announced that it has received $0.71184 million in funding CI
07-09 Oncotelic Therapeutics, Inc. announced that it expects to receive $0.71184 million in funding CI
07-07 Oncotelic Therapeutics, Inc. and Sapu Nano (Us) LLC Advance Joint Clinical Program and Expand European Clinical Sites CI
06-29 Oncotelic Therapeutics, Inc. and Sapu Nano Announce Peer-Reviewed Validation of Deciparticle Platform Supporting Clinical Development of Sapu003 CI
06-22 Oncotelic Therapeutics, Inc. announced that it has received $0.157001 million in funding from Pacific Pier Capital Ii, Llc CI
06-18 Oncotelic Therapeutics, Inc. Launches AI-Powered GMP Manufacturing Services Platform At BIO International Convention 2026 CI
06-17 Oncotelic Therapeutics, Inc. And TechForce Robotics, Inc. Advance AI-Powered GMP Manufacturing Services Platform For Revenue-Generating AI And Robotics Manufacturing Services CI
06-17 TechForce Robotics Advances Phase 2 Deployment Of PUR-E Autonomous Clean Room Support Robot At SAPU Bio OEB-5 Sterile Injectable cGMP Facility CI
06-08 Oncotelic Therapeutics, Inc. Showcases Pdaoai Capability in Advancing Drug Development CI
05-14 Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-13 Sapu Nano And Oncotelic Therapeutics, Inc. Announce First Patient Dosed In Phase 1b Trial Of Sapu003, An Intravenous Deciparticle Formulation Of Everolimus CI
1 day-10.96%
1 week+1.81%
Current month-23.18%
1 month-33.20%
3 months-51.71%
6 months-55.29%
Current year-78.44%
1 week 0.02
Extreme 0.0161
0.02
1 month 0.02
Extreme 0.015
0.03
Current year 0.02
Extreme 0.015
0.09
1 year 0.02
Extreme 0.015
0.11
3 years 0.02
Extreme 0.015
0.11
5 years 0.01
Extreme 0.01
0.26
10 years 0.01
Extreme 0.01
0.38
Manager TitleAgeSince
Chief Executive Officer 61 2019-04-21
Director of Finance/CFO 59 2019-06-30
Chief Tech/Sci/R&D Officer 77 2020-01-05
Director TitleAgeSince
Chairman 61 2019-04-21
Director/Board Member 61 2020-05-10
Director/Board Member 61 2020-05-10
Date Insider Type Main position Quantity % Market Cap. Importance
7/10/26
Autotelic, Inc.
OtherCompany 0 0% -
7/10/26 Other

Chief Executive Officer

0 0%
7/1/26 Buy

Chief Executive Officer

240,000 0.0540%
Change 5-day change 1-year change 3-year change Capi.($)
-10.96%+1.81%-81.43%-57.75% 7.73M
+2.41%+0.29%+39.41%+73.38% 64.69B
-0.15%+7.50%+11.42%+75.22% 54.78B
+0.57%+4.60%+7.71%+100.57% 53.49B
+0.37%+4.67%+26.68%+54.16% 45.98B
-1.21%+2.32%+21.50%+126.83% 42.94B
-0.37%+5.07%+243.23%+834.48% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%+0.33% 23.97B
-0.38%+5.68%+38.39%+29.86% 23.67B
Average -0.85%+2.35%+35.13%+128.56% 38.31B
Weighted average by Cap. +0.39%+2.73%+46.02%+151.31%

Financials

2024 2025
Net sales - -
Net income -4.52M -4.04M -3.73M -3.38M -6.33M -429M -6.43M -44.91M -17.78M -225M -16.98M -16.62M -709M 249M 223M 206M 186M 349M 23.66B 354M 2.47B 980M 12.4B 936M 916M 39.09B
Net Debt 13M 11.61M 10.73M 9.72M 18.19M 1.23B 18.49M 129M 51.1M 647M 48.8M 47.76M 2.04B 13.82M 12.34M 11.4M 10.33M 19.33M 1.31B 19.65M 137M 54.33M 688M 51.88M 50.78M 2.17B
Projected Income Statement - Annual - Oncotelic Therapeutics, Inc.
Logo Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small-molecule injectable drugs for the treatment of cancer. The Company has three primary drugs and AI technology programs: AL-101 - Intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson’s Disease (PD), erectile dysfunction (ED) and female sexual dysfunction (FSD); CA4P- a vascular disrupting agent (VDA) - in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma; Oxi4503- a second generation VDA - for the treatment of liquid tumors with focus on childhood leukemia; OT-101 - an antisense against TGF-b2-for the treatment of various cancers and for the treatment of various viruses, and Artemisinin-a natural derivative from an Asian herb Artemisia Annua.
Employees
41
Date Price Change Volume
26-10-23 US$0.0169 -10.96% 254,129
26-10-22 US$0.0190 +3.15% 57,101
26-10-21 US$0.0184 +4.72% 238,259
26-10-20 US$0.0176 -5.03% 227,042
26-10-19 US$0.0185 +11.45% 204,601
  1. Stock Market
  2. Stocks
  3. OTLC Stock